Lenalidomide and Dexamethasone for Rosai-Dorfman Disease
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Rosai-Dorfman Disease (RDD) is a rare, heterogeneous histiocytic disorder. Because of the
rarity of RDD and a lack of prospective randomized trials, the treatment strategy for RDD is
mostly based on retrospective study. Steroid was suggested as frontline treatment as RDD with
only lymph nodes involvement. Studies showed thalidomide or lenalidomide showed some effect
in recurrent/refractory skin RDD. The investigators want to analyze the efficacy and toxicity
of lenalidomide combined with dexamethasone regimens in the treatment of RDD among adult
patients at our hospital.